And so it begins. Here's an illustration of the lenz-enhanced Novavax covid and CIC vaccines on the road to taking the bird flu vaccine market away from the Moderna mRNA product.
The as-yet untapped covid market for Humanigen is for infected patients who do not presently need hospitalization. With a potential IM formulation of lenz in our HGEN/IPIX/GBLX product, will we be able to treat infected patients much earlier in a stage of disease progression and thereby relieve demand on our healthcare infrastructure?